GoodRx Q1 2024 revenue $197.9M; adjusted EBITDA $62.8M

GoodRx Holdings, Inc.

2024-Q1 EPS reported $0.00 revenue$197,880,000

Revenue (GAAP and adjusted) of $197.9M; net loss $1.0M; adjusted net income $32.6M.
Adjusted EBITDA $62.8M (31.7% margin); operating cash flow $42.6M.
Exited Q1 with ~8 million consumers of prescription-related offerings.
Interim CEO Scott Wagner cites progress and path to return to 'Rule of 40' company.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GoodRx Holdings, Inc. reported the three months ended March 31, 2024 results: revenue $197.9 million, net income Net loss of $1.0 million.

Period: the three months ended March 31, 2024
Revenue: $197.9 million
Net income: Net loss of $1.0 million
Result: reported results

Exact text from the filing

for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights • Revenue 1 and Adjusted Revenue 1 of $197.9 million • Net loss of $1.0 million; Net loss margin of 0.5% • Adjusted Net Income 1 of $32.6 million; Adjusted Net Income Margin 1 of 16.5% • Adjusted EBITDA 1 of $62.8 million; Adjusted

View on SEC.gov

1051 earnings releases filed in the last 30 days. Browse all earnings releases →

GoodRx Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001809519-24-000081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.